We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LMND:NYSELemonade, Inc. Analysis

Data as of 2026-05-25 - not real-time

$56.52

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Lemonade’s stock is trading at $56.52, well below its 20‑day ($56.14), 50‑day ($60.29) and 200‑day ($63.89) simple moving averages, signaling a bearish technical backdrop. The price sits just above the identified support at $50.80 and faces resistance near $68.05, while the RSI of 48 indicates neutral momentum and a bullish MACD histogram (+0.40) hints at a possible short‑term reversal. However, volume is on a decreasing trend and 30‑day volatility is extremely high at 74.7%, compounded by a beta of 2.79, underscoring significant price swings.
Fundamentally, LMND posted a remarkable 70.6% revenue growth to $844.7 M and generated positive free cash flow of $90.9 M, yet it remains unprofitable with a –11% operating margin and a forward P/E of –150.7. The DCF‑derived fair value of $44.6 is well beneath the current market price, suggesting the stock is priced above intrinsic estimates. While cash balances (~$394 M) comfortably exceed debt (~$200 M), the high debt‑to‑equity ratio (≈38.7) and negative ROE highlight financial strain. Analyst consensus leans “hold” with a median target of $62, and the market sentiment index reads “Extreme Greed,” reflecting optimism despite the underlying risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price trading below short‑term SMA levels
  • Decreasing volume and elevated 30‑day volatility
  • Recent earnings miss and negative profit margins

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained ~70% revenue growth and accelerating in‑force premiums
  • Positive free cash flow despite operating losses
  • Potential upside toward analyst median target around $62

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Current price exceeds DCF fair value, indicating overvaluation
  • Persistent operating losses and high beta increase downside risk
  • Long‑term franchise potential with AI‑driven insurance model

Key Metrics & Analysis

Financial Health

Revenue Growth70.60%
Profit Margin-16.44%
P/E Ratio-150.7
ROE-26.12%
ROA-3.51%
Debt/Equity38.69
P/B Ratio8.0
Op. Cash Flow$30.1M
Free Cash Flow$90.9M
Industry P/E16.8

Technical Analysis

TrendBearish
RSI48.0
Support$50.80
Resistance$68.05
MA 20$56.14
MA 50$60.29
MA 200$63.89
MACDBullish
VolumeDecreasing
Fear & Greed Index91.71

Valuation

Fair Value$44.60
Target Price$59.56
Upside/Downside5.37%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.79
Volatility74.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.